Poh Chin Leng, Zannino Diana, Weintraub Robert G, Winlaw David S, Grigg Leeanne E, Cordina Rachael, Hornung Tim, Bullock Andrew, Justo Robert N, Gentles Thomas L, Verrall Charlotte, du Plessis Karin, Celermajer David S, d'Udekem Yves
Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia; Murdoch Childrens Research Institute, Heart Research Group, Melbourne, VIC, Australia.
Murdoch Childrens Research Institute, Clinical Epidemiology & Biostatistics, Melbourne, VIC, Australia.
Int J Cardiol. 2017 Mar 15;231:99-104. doi: 10.1016/j.ijcard.2017.01.057. Epub 2017 Jan 7.
To review our experience of patients with an atrio-pulmonary Fontan circulation to determine their long-term outcomes.
A retrospective analysis of long-term follow-up data using the Australia and New Zealand Fontan Registry was performed. There were 215 patients surviving hospital discharge after an atrio-pulmonary Fontan completion. A total of 163 patients were alive at latest follow-up, with 52 deaths. Twelve patients had required heart transplantation and 95 had Fontan failure (death, transplantation, Fontan takedown, Fontan conversion, severe systemic ventricular dysfunction or NYHA≥3). Twenty-eight year freedom from death, death and transplantation and Fontan failure were 69% (95% CI 61-78%), 64% (95% CI 56-74%) and 45% (95% CI 36-55%) respectively. One hundred and thirty patients developed atrial arrhythmias. Freedom from arrhythmia at 28years post Fontan was 22.9% (95% CI: 15.1-30.8). Development of arrhythmia increased the likelihood of death (HR:2.97, 95%CI 1.50-5.81; p=0.002), death and heart transplantation (HR:3.11, 95%CI 1.64-5.87; p<0.001) and Fontan failure (HR:4.78 95%CI 2.95-7.74; p<0.001). There were 42 patients who had thromboembolic events, of which only 12 were therapeutically anti-coagulated. Two-thirds of the surviving patients (86/126) with an intact atrio-pulmonary Fontan were regularly reviewed. Patients receiving follow-up care with general cardiologists without specialised training were more likely to face Fontan failure than those managed by cardiologists with specialist training in congenital heart disease (HR: 1.94, 95% CI 1.16-3.24; p=0.02). The majority of the surviving patients (81/86) remained physically active and almost two-thirds (54/86) were currently employed.
Two-thirds of the patients who underwent a classical atrio-pulmonary Fontan are still alive 3 decades later. The majority are affected by the burden of arrhythmias but remain functionally active today. These challenging patients should only receive follow-up care from cardiologists with specialised training.
回顾我们对接受心房-肺动脉Fontan循环患者的治疗经验,以确定其长期预后。
利用澳大利亚和新西兰Fontan注册中心的数据对长期随访资料进行回顾性分析。215例患者在完成心房-肺动脉Fontan手术后存活出院。在最近一次随访时,共有163例患者存活,52例死亡。12例患者需要进行心脏移植,95例发生Fontan循环衰竭(死亡、移植、拆除Fontan、转换Fontan、严重的体循环心室功能障碍或纽约心脏协会心功能分级≥3级)。28年无死亡、无死亡及移植和无Fontan循环衰竭的生存率分别为69%(95%可信区间61%-78%)、64%(95%可信区间56%-74%)和45%(95%可信区间36%-55%)。130例患者发生房性心律失常。Fontan手术后28年无心律失常的生存率为22.9%(95%可信区间:15.1%-30.8%)。发生心律失常增加了死亡(风险比:2.97,95%可信区间1.50-5.81;P=0.002)、死亡及心脏移植(风险比:3.11,95%可信区间1.64-5.87;P<0.001)和Fontan循环衰竭(风险比:4.78,95%可信区间2.95-7.74;P<0.001)的可能性。42例患者发生血栓栓塞事件,其中仅12例接受了抗凝治疗。三分之二存活的心房-肺动脉Fontan循环完整的患者(86/126)接受了定期复查。由未接受专门培训的普通心脏病专家进行随访的患者比由接受先天性心脏病专门培训的心脏病专家管理的患者更易发生Fontan循环衰竭(风险比:1.94,95%可信区间1.16-3.24;P=0.02)。大多数存活患者(81/86)仍保持身体活动,近三分之二(54/86)目前仍在工作。
三分之二接受经典心房-肺动脉Fontan手术的患者在30年后仍然存活。大多数患者受到心律失常的困扰,但目前功能仍然良好。这些具有挑战性的患者应该仅由接受专门培训的心脏病专家进行随访。